[Basophil activation test as in vitro assay for cisplatin allergy].
During chemoembolization with gemcitabine, mitomycin and cisplatin of a cholangiocellular carcinoma and after receiving iodide contrast media, a 49-year-old patient developed a grade III anaphylactic reaction. We were asked to verify an adverse reaction to contrast media. Using the basophil activation test, we demonstrated a hypersensitivity reaction to cisplatin with distinct induction of CD63-expression on basophilic granulocytes.
Viardot-Helmer
A
A
Hautklinik, Universitätsklinikum der RWTH Aachen, Pauwelsstrasse 30, 52074 Aachen, Deutschland. ahelmer@ukaachen.de
Ott
H
H
Sauer
I
I
Merk
H F
HF
D000707:Anaphylaxis / Q000139:chemically induced* / Q000175:diagnosis* / Q000276:immunology; D015703:Antigens, CD / Q000276:immunology*; D000970:Antineoplastic Agents / Q000009:adverse effects; D015549:Basophil Degranulation Test / Q000379:methods*; D002945:Cisplatin / Q000009:adverse effects*; D003875:Drug Eruptions / Q000175:diagnosis* / Q000209:etiology* / Q000276:immunology; D006801:Humans; D008297:Male; D008875:Middle Aged; D010980:Platelet Membrane Glycoproteins / Q000276:immunology*; D060149:Tetraspanin 30
D015703:Antigens, CD; D000970:Antineoplastic Agents; C554586:CD63 protein, human; D010980:Platelet Membrane Glycoproteins; D060149:Tetraspanin 30; D002945:Cisplatin